Antonio Gioradano, MD, presents efficacy and safety of atirmociclib + fulvestrant in HR+/HER2- advanced breast cancer after progressing on prior CDK4/6 inhibitor - data from phase 2 FOURLIGHT-1 study.
I'm very excited to present the first randomized data of a thermocyclib, a potential first in class CDK4 inhibitor in a patient with hormone receptor positive, HER2 negative, advanced or metastatic breast cancer who progressed on a prior CDK4 6 inhibitor. Um, we know that, uh, CDK46 inhibitor are the main stem, the, of the, uh, uh, first line treatment for HR positive HER2 negative breast cancer, but unfortunately, uh, ultimately, uh, majority of the patient will progress and that's a very, uh, high clinical unmet need. Uh, athermocyclib with the, uh, is a potent CDK4 selective inhibitor that can spare CDK6, so can achieve a better, um, activity in your positive breast cancer, um, with less myelosuppression. 44 line one enrolled approximately 260 patients and the patients were randomized 1 to 1 to either athermocyclib plus Fulvestrin or investigator choice of therapy or ICT of either Fulvestrin of exemesin plus severolimus. This was a randomized phase two study. That, um, uh, enrolled patients from, uh, around the world, and, uh, um, the, uh, primary endpoint of the study was progression free survival. Uh, in the study, after about 14 months median follow-up time, the, uh, treatment with a thermocyclic plus fulvestrin reduced, By 40%, the chance of, uh, recurrence, uh, or death, uh, compared to the ICT arm. The median progression free survival for, uh, patient that received the thermocyclib, uh, plus fulvestrin was 9.4 months versus 6.6 months in the patient with the, uh, the, Received the, uh, ICT. In all the subgroup analysis, athermocyclib showed, uh, to be the favorable, uh, treatment compared to the ICT across all the subtypes. Uh, and, uh, the, um, the study, uh, uh, enhanced the, uh, further development of this drug now in the earlier, Line, including the uh phase 3 randomized trial in the first line setting where athermocyclib has been compared to the uh uh currently approved CDK 46 inhibitor, the 4 light 3 study that has uh completed a CUL and uh we may see results uh in the uh upcoming uh year.